BMF

Across TCGA pan-cancer cohorts, BMF Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated BMF data layer compared with 18 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher BMF Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated BMF expression acts as an unfavorable survival marker.

STAD and HNSC are the cancer types where BMF Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	DFS	Median	All	0.198	0.660	<.001	33	view →
HNSC	DFS	Median	All	0.136	0.625	.049	3	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

BMF–STAD (DFS)

Open the STAD breakdown →